课题基金 / 基金详情

Development of a novel paradigm for local antimicrobial chemotherapy: bacterial protease activated antimicrobial release from hydrogel device coatings

Development of a novel paradigm for local antimicrobial chemotherapy: bacterial protease activated antimicrobial release from hydrogel device coatings
开发局部抗菌化疗的新范例:细菌蛋白酶激活水凝胶装置涂层中的抗菌剂释放
批准号:
BB/F005164/1
负责人:
Brendan Gilmore
金额:
$41.02万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2008
资助国家:
英国
项目状态:
已结题
起止时间:
2008 至 --

项目摘要

项目成果

Brendan Gilmore的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
In the UK improved healthcare and a steadily growing population has resulted in an increase in the average male and female life expectancy and a steadily aging UK population. An increase in the population, but especially the elderly or aging population, is set to have major consequences for the NHS. The aging population requires a greater number of medical treatments, hospital admissions and surgical/corrective procedures. In this respect, the use of medical devices (such as catheters) which are inserted into the patients body (to aid or support it's normal functions) are now routinely and frequently used in a variety of clinical settings. Although the use of inserted medical devices has substantial benefits, a worryingly high incidence of potentially serious complications has been reported. In general, complications associated with inserted medical devices lead to an increase in the time spent by patients in hospital, readmissions to hospital and in very serious cases, increase in patient deaths. One of the most common problems arising in the use these devices is the infection associated with the device, where bacteria or fungi grow on the device surface and form a 'protected community' called a biofilm. Once biofilms form on the device it is extremely difficult to treating the infection, once established, without having to remove the device. Depending on the site of the medical device this can be either a simple (urinary tract), if uncomfortable and inconvenient, process or may require serious and life-threatening surgery (i.e. venous catheters or heart prostheses). This aspect of the use of inserted medical devices is the most serious and critical disadvantage to what is otherwise a highly effective, beneficial and often simple medical treatment. Clearly, there is an urgent need to improve the current situation by the development of new and innovative medical devices which actively resist and prevent infection, thereby reducing the incidence of medical device-related infection. The main objective of this research proposal is to improve effectiveness and quality of life for patients who require such medical devices via the development of new, innovative materials which respond to the presence of infecting microorganisms by the release of antibiotic agents. During infection, bacteria use very specific enzymes to break down surrounding tissue proteins and other molecules. This project is aims to harness these very specific protein cutting enzymes, known as proteases, to activate antibiotic release from novel device coatings. In this way antibiotic molecules are released only when the infecting bacteria are present during the development of device-related infection. Antibiotics will accumulate at the device surface at concentrations necessary to kill the infecting bacteria, thus protecting the device, and ultimately the patient, from associated infections. Antibiotic release is thus coordinated with the presence of the infecting microorganisms, such that the device is not permanently releasing drug / a situation difficult to maintain in the long-term and a feature that has been shown to lead to emergence of resistant bacteria such as MRSA. The primary outcome of this project is to improve the highly unsatisfactory situation for patients whose therapy relies on inserted medical device usage by improving the antimicrobial activity and lifetime of these devices. The project will also furnish clear benefits to the NHS by reducing the costs associated with this medical treatment by reducing length hospital stays and readmissions. This will ultimately free funding for numerous other healthcare initiatives and programmes, thus improving overall service provided to patients by the NHS. Furthermore, the benefits of the development of such innovative technologies provide benefits to the medical devices industry by the generation of value-added products, allowing the UK to compete effectively in the world market place.
期刊论文(9)
专著(0)
科研奖励(0)
会议论文
Intelligent anti-infective biomaterials
智能抗感染生物材料
DOI: --
发表时间: 2008
期刊: Journal of Pharmacy & Pharmacology
影响因子: --
作者: [Croskery AJ]
通讯作者: Croskery AJ
DOI: --
发表时间: 2013
期刊:
影响因子: --
作者: [Gilmore BF]
通讯作者: Gilmore BF
A Novel Bacterial Protease-triggered Polymeric Antimicrobial Release System
一种新型细菌蛋白酶触发的聚合抗菌释放系统
DOI: --
发表时间: 2011
期刊: Proceedings of the 2nd European Congress on Microbial Biofilms - Basic & Clinical Aspects
影响因子: --
作者: [Chen W]
通讯作者: Chen W
Proteases as selective activators of triggered drug release
蛋白酶作为触发药物释放的选择性激活剂
DOI: --
发表时间: 2011
期刊: UKICRS Newsletter
影响因子: --
作者: [Chen W]
通讯作者: Chen W
7
    Cold Plasma to Treat Post-Surgical Orthopedic Infection
    • 批准号:
      MC_PC_20019
    • 项目类别:
      Intramural
    • 资助金额:
      $22.3万
    • 财政年份:
      2020
    • 负责人:
      Brendan Gilmore
    • 依托单位:
    EnvironSafe: Cold Plasma Innovations for Food Safety and Sustainability
    • 批准号:
      BB/P008496/1
    • 项目类别:
      Research Grant
    • 资助金额:
      $82.82万
    • 财政年份:
      2017
    • 负责人:
      Brendan Gilmore
    • 依托单位:
    国内基金
    海外基金
    Novel-miR-1134调控LHCGR的表达介导拟 穴青蟹卵巢发育的机制研究
    • 批准号:
    • 项目类别:
      省市级项目
    • 资助金额:
      10.0万元
    • 批准年份:
      2025
    • 负责人:
      崔文晓
    • 依托单位:
    novel-miR75靶向OPR2,CA2和STK基因调控人参真菌胁迫响应的分子机制研究
    • 批准号:
      82304677
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      30.00万元
    • 批准年份:
      2023
    • 负责人:
      边兴博
    • 依托单位:
    海南广藿香Novel17-GSO1响应p-HBA调控连作障碍的分子机制
    • 批准号:
      82304658
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      30万元
    • 批准年份:
      2023
    • 负责人:
      刘亚
    • 依托单位:
    白术多糖通过novel-mir2双靶向TRADD/MLKL缓解免疫抑制雏鹅的胸腺程序性坏死
    • 批准号:
      32102747
    • 项目类别:
      青年科学基金项目(C类)
    • 资助金额:
      30.0万元
    • 批准年份:
      2021
    • 负责人:
      李婉雁
    • 依托单位: